Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

昔服申 - NMPA Drug Approval Details

Approvals/NMPA/Rifaximin Tablets

Approved

化学药品

Rifaximin Tablets

ALFASIGMA SPA🇨🇳 National Medical Products Administration

Approval Date: Jun 7, 2023
Approval ID: 8TEL1TNpdrx
Company: ALFASIGMA SPA
Type: 化学药品

Approval Details

Approval Id: 8TEL1TNpdrx
Approval Number: 国药准字HJ20181212
Generic Name: 利福昔明片
Generic Name En: Rifaximin Tablets
Trade Name: 昔服申
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 0.2g
Reg Date: 2023-06-07
Expired Date: 2028-06-06
Company Name: ALFASIGMA SPA
Production Company Name: ALFASIGMA SPA
Company Detail Path: /organization/alfasigma-spa
Production Company Detail Path: /organization/alfasigma-spa

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jun 7, 2023

Approval ID

8TEL1TNpdrx

Type

化学药品

Back to NMPA Approvals